Follow-up of tuberculosis patients undergoing standard anti-tuberculosis chemotherapy by using a polymerase chain reaction

LeVee, Gordon J.; Glaziou, Philippe; Gicquel, Brigitte; Chanteau, Suzanne

doi:10.1016/0923-2508(94)90061-2

Cited by 23 publications

(17 citation statements)

References 4 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Hellyer et al, Levee et al, and Thomsen et al (8,13,25) previously demonstrated that M. tuberculosis DNA could be detected by strand displacement amplification and PCR in frozen sputum samples more than 12 months after the initiation of treatment and more than 6 months after positive-tonegative culture conversion. The differences found between the two amplification systems could be explained by differences in the extraction methods used or by a reduction in the amount of inhibitory factors.…”

Section: Discussionmentioning

confidence: 99%

Comparison of the COBAS AMPLICOR MTB and BDProbeTec ET Assays for Detection of Mycobacterium tuberculosis in Respiratory Specimens

et al. 2005

View full text Add to dashboard Cite

The performances of the BDProbeTec ET (Becton Dickinson) and COBAS AMPLICOR MTB (Roche) were retrospectively evaluated for detecting Mycobacterium tuberculosis complex in various respiratory specimens. The BACTEC and MGIT liquid culture system (Becton Dickinson) was used as a reference method. A total of 824 respiratory specimens, comprised of sputa, bronchoalveolar lavage fluid, and bronchial and tracheal aspirates from 580 patients, were evaluated. Out of 824 clinical specimens, 109 specimens from 43 patients were culture positive for M. tuberculosis. Of these 109 specimens, 67 were smear positive, 85 were positive by the COBAS AMPLICOR MTB test, and 94 were positive by the BDProbeTec ET. Of the 715 culture-negative specimens, 17 were positive by the auramine staining, 11 were positive by the COBAS AMPLICOR MTB test, and 12 were positive by the BDProbeTec ET. After discrepancy analysis and review of the patients' clinical data, 130 specimens from 50 patients were considered "true-positive" specimens. This resulted in the following sensitivities: microscopy, 61.5%; COBAS AMPLICOR MTB test, 78.0%; and BDProbeTec ET, 86.2%. The specificities of each system, based on the clinical diagnosis, were 99.7% for microscopy, 99.9% for the COBAS AMPLICOR MTB test, and 99.9% for the BDProbeTec ET. The data presented represent a considerable number of specimens evaluated with a considerable number of culture-and auramine-positive and culturepositive and auramine-negative results and therefore give a realistic view of how the data should be interpreted in a daily routine situation. Specifically, the data with regard to the culture-positive and auramine-negative specimens are useful, because in a routine situation, auramine-negative specimens are sometimes accepted, on clinical indications, to be analyzed by an amplification method.In contrast to general expectations, the incidence of mycobacterial disease has significantly increased worldwide since 1990 (7). The technical developments in diagnosing infections caused by Mycobacterium tuberculosis have increased similarly, an important change being the replacement of traditional solid culture media by liquid media and the introduction of molecular amplification techniques, such as PCR, has decreased the turnaround time even further (1, 22). Many commercial assays are now available; for instance, the COBAS AMPLICOR MTB system (Roche, Basel, Switzerland) uses PCR (4, 27), while the BDProbeTec ET system (14) from Becton Dickinson (Sparks, Md.) uses the "strand displacement amplification" technique for detecting M. tuberculosis (3,5,6,8,11,23,24,26).Amplification techniques have a good sensitivity for smearpositive specimens; however, for smear-negative samples, the reported sensitivity varies considerably (16,17,18,21).The objective of the present study was to compare the sensitivities and specificities of the BDProbeTec ET and the COBAS AMPLICOR MTB properly by evaluating the assays with the same set of processed specimens. Secondly, as the smear-negative specimens influence the ...

show abstract

Section: Discussionmentioning

confidence: 99%

Comparison of the COBAS AMPLICOR MTB and BDProbeTec ET Assays for Detection of Mycobacterium tuberculosis in Respiratory Specimens

et al. 2005

View full text Add to dashboard Cite

show abstract

“…44 Results of previous PCR studies have noted a longer time to negativity (2-6 months) after initiation of therapy. 45,46 Perhaps the greater stability of DNA compared with RNA account for the increased time to test negativity in PCR tests.…”

mentioning

confidence: 99%

Comprehensive Evaluation of Performance, Laboratory Application, and Clinical Usefulness of Two Direct Amplification Technologies for the Detection ofMycobacterium tuberculosisComplex

Della‐Latta

Whittier

1998

Am J Clin Pathol

View full text Add to dashboard Cite

A b s t r a c t The rapid detection of Mycobacterium tuberculosis from respiratory specimens is critical for optimal treatment of patients. Several nucleic acid amplification-based systems designed to detect3 Nevertheless, reliance on growth-dependent techniques that can be insensitive and lengthy (2-8 weeks) have placed the laboratory in a retrospective diagnostic picture. The advent of nucleic acid amplification technology and its application to the diagnostic arena promises sweeping changes that place the laboratory in a pivotal position to directly influence the clinical diagnosis of TB by providing same-day detection of the pathogen.The ultrasensitive nature of the direct amplification tests (DATs) makes them susceptible to false-positive reactions, particularly with unstandardized "home-brew" polymerase chain reaction (PCR) systems, 4 underscoring the need for assays that provide accurate reproducible results under controlled conditions. Several manufacturers have simplified and standardized molecular technology by formulating userfriendly commercial kits marketed for use in the routine clinical microbiology laboratory for the detection of MTB complex in respiratory specimens. These assays are designed to supplement, not replace, culture, which remains essential for drug susceptibility testing, detection of nontuberculous mycobacteria (NTM), and fingerprinting of MTB strains for epidemiologic investigations or documentation of specimen cross-contamination. Nevertheless, in-house PCR test systems persist, offering less costly alternatives to commercial systems in exchange for reduction in interlaboratory correlation and standardization.

show abstract

“…The low specificity of the three PCR tests could be due to the presence of nonviable organisms in patients receiving therapy and the inadequate sensitivity of the reference culture method. Published experience with PCR supports the concept that a patient can remain PCR positive after cultures have become negative (8,10).…”

Section: Resultsmentioning

confidence: 94%

Comparison of the Roche AMPLICOR MYCOBACTERIUM assay and Digene SHARP Signal System with in-house PCR and culture for detection of Mycobacterium tuberculosis in respiratory specimens

et al. 1996

View full text Add to dashboard Cite

Two commercial primer kits and detection systems, the Roche AMPLICOR MYCOBACTERIUM test and the Digene primer-probe kit with the SHARP Signal System, were compared to in-house PCR as well as standard culture techniques. For the 27 culture-positive specimens, the Roche AMPLICOR MYCOBACTE-RIUM test detected 20 specimens, the Digene system detected 19, and in-house PCR detected 21. Of the 86 culture-negative specimens, 13 were positive by the Roche AMPLICOR MYCOBACTERIUM test, 16 were positive by the Digene system, and 21 were positive by in-house PCR. When clinical situations were evaluated, 11 of 13 culture-negative Roche AMPLICOR MYCOBACTERIUM test-positive specimens, 10 of 16 culturenegative Digene system-positive specimens, and 13 of 21 culture-negative-in-house PCR-positive specimens were diagnosed as true-positive specimens. The sensitivities of Roche AMPLICOR MYCOBACTERIUM test, the Digene system, and in-house PCR were 73.81, 69.05, and 80.95%, and the specificities were 97.18, 91.55, and 88.73%, respectively. The positive predictive values were 93.94, 82.86, and 80.95%, and the negative predictive values were 86.25, 83.33, and 88.73%, respectively. For the commercial kits, the Roche AMPLICOR MYCO-BACTERIUM test seems to be more sensitive and specific than the Digene system. However, the Roche AMPLICOR MYCOBACTERIUM test cannot be used on nonrespiratory specimens.

show abstract

Follow-up of tuberculosis patients undergoing standard anti-tuberculosis chemotherapy by using a polymerase chain reaction

Cited by 23 publications

References 4 publications

Comparison of the COBAS AMPLICOR MTB and BDProbeTec ET Assays for Detection of Mycobacterium tuberculosis in Respiratory Specimens

Comparison of the COBAS AMPLICOR MTB and BDProbeTec ET Assays for Detection of Mycobacterium tuberculosis in Respiratory Specimens

Comprehensive Evaluation of Performance, Laboratory Application, and Clinical Usefulness of Two Direct Amplification Technologies for the Detection ofMycobacterium tuberculosisComplex

Comparison of the Roche AMPLICOR MYCOBACTERIUM assay and Digene SHARP Signal System with in-house PCR and culture for detection of Mycobacterium tuberculosis in respiratory specimens

Contact Info

Product

Resources

About